

Press Release

SORIN GROUP: SHAREHOLDERS' ASSEMBLY APPOINTED NEW BOARD OF DIRECTORS FOR THE 2009-2011 PERIOD

Milan, December 30, 2008 – The Shareholders meeting of Sorin S.p.A, convened today in Milan for the purpose of appointing a new Board of Directors, having first determined the number of members to be appointed to that new Board. 52 shareholders were present – either in person or via delegates – representing 54,98% of the total share capital.

To appoint the new Board, the shareholders voted on the basis of the lists presented to the Company by the shareholders BIOS S.p.A., MPS Investments S.p.A. and BIOS Interbanca S.p.A..

The Shareholders Meeting also set fifteen as the number of Directors and named the new Board of Directors for a three-year period (2009-2011).

Those elected from the list presented by BIOS S.p.A. (majority list) are: Rosario Bifulco, André-Michel Ballester, Giovanni Gorno Tempini, Andrea Bovone, Francesco Silva, Giovanni Pavese, Paolo Baessato, Ettore Morezzi, Claudio Agostino Zulli and Giuliano Asperti.

From the list presented by MPS Investments S.p.A. (minority list) has been elected Enzo Nicoli.

Those elected from the list presented by Bios Interbanca S.p.A., (minority list) are: Paolo Braghieri, Michele Cappone, Luca Di Giacomo and Gabriele Casati.

The members of the Board who declared their independence include: Rosario Bifulco, Paolo Baessato, Ettore Morezzi, Giuliano Asperti, Enzo Nicoli, Michele Cappone, Luca Di Giacomo and Gabriele Casati. These individuals declared to have the prerequisites to be independent Board Members according to Article 148, paragraph 3 of the Italian decree, the "Testo Unico".

The New Board of Directors will meet on January 8th, 2009 to allocate the executive powers.

About the Sorin Group

The Sorin Group (www.sorin.com), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, and the treatment of chronic kidney diseases. At the Sorin Group, more than 3,500 employees work to serve over 5,000 public and private treatment centers. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.

For more information, please visit: www.sorin.com or contact:

Martine Konorski
Director, Corporate Communications

Carla Vidra
Investor Relations